Comparison of osteoporosis pharmacotherapy fracture rates: Analysis of a marketScan® claims database cohort [PDF]
, 2018 Background: Several different classes of medications have been shown to be efficacious at preventing fractures in patients with osteoporosis. No study has compared real world efficacy at preventing fractures between all currently approved medications ...
Fox, Edward J. +5 more
core +2 more sources
BISPHOSPHONATE INDUCED OSTEONECROSIS OF THE JAWS AND CURRENT THERAPIES
Cumhuriyet Dental Journal, 2017 Bisphosphonates are pharmacological agents which are the potent inhibitors of osteoclastic activity. Nowadays, bisphosphonates are used to treat a variety of bone disease or related complications such as metastatic or osteolytic bone disease ...
Damla Torul, Mehmet Cihan Bereket
doaj +1 more source
ATYPICAL FRACTURES DUE TO LONG TREATMENT WITH BISPHOSPHONATES (CRITICAL REVIEW)
Travmatologiâ i Ortopediâ Rossii, 2013 This paper reviews the evidence for an association between atypical subtrochanteric fractures and long-term bisphosphonate use. A PubMed search of literature was performed.
G. S. Golubev
doaj +1 more source
Tiludronate and clodronate do not affect bone structure or remodeling kinetics over a 60 day randomized trial [PDF]
, 2018 Background Tiludronate and clodronate are FDA-approved bisphosphonate drug therapies for navicular disease in horses. Although clinical studies have determined their ability to reduce lameness associated with skeletal disorders in horses, data regarding
Gillett, Ashley N. +3 more
core +1 more source
Journal of Education, Health and SportIntroduction: Bisphosphonates are pharmacological agents that inhibit bone resorption by targeting osteoclasts, thereby increasing bone density and reducing fracture risk.
Agnieszka Mikosińska +8 more
doaj +1 more source
Bisphosphonates and osteonecrosis of jaws
Journal of Indian Academy of Oral Medicine and Radiology, 2012 Bisphosphonates are used to treat osteoporosis. Paget disease of bone and other metabolic bone diseases, multiple myeloma, and skeletal events associated with metastatic neoplasms- In 2003, the first reports describing osteonecrosis of the jaw (ONJ) in ...
Geetha Vijay, Vijay Raghavan
doaj +1 more source
Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial. [PDF]
, 2019 ObjectiveTo evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoid arthritis (RA).MethodsThis was a multi-centre ...
Genant, Harry K +9 more
core +2 more sources
Saudi Pharmaceutical Journal, 2018 Introduction: In October 2010, the US Food and Drug Administration (FDA) issued a safety communication regarding the risks of atypical fractures of the femur, with bisphosphonates drugs.
Bander Balkhi +2 more
doaj +1 more source
Effects of Bisphosphonates on Bone Micro-Architecture of Children With Duchenne Muscular Dystrophy: A Prospective Comparative Study. [PDF]
J Cachexia Sarcopenia MuscleABSTRACT Background Duchenne muscular dystrophy (DMD) is an X‐linked recessive disorder that affects dystrophin production, characterized by progressive neuromuscular dysfunction, often accompanied by osteoporosis. We prospectively evaluate the effects of bisphosphonates on bone micro‐architecture reflected by trabecular bone score (TBS) of patients ...
Wang S +11 more
europepmc +2 more sources
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis [PDF]
, 2006 BACKGROUND: Treatment with glucocorticoids is associated with bone loss starting soon after therapy is initiated and an increased risk of fracture. METHODS: We performed a randomized, double-placebo, double-blind clinical trial of 18 months' duration ...
Ale Algra +14 more
core +4 more sources